Compare Stocks: CRIS, LGVN, XCUR, and SKYE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRIS Curis	$0.83 +0.2%	$2.36	$0.80 ▼ $34.80	$1.73M	3.01	142,476 shs	158,284 shs
LGVN Longeveron	$2.63 -6.4%	$6.32	$2.30 ▼ $12.30	$8.96M	-0.25	177,635 shs	96,990 shs
SKYE Skye Bioscience	$1.61 -3.6%	$2.99	$1.50 ▼ $39.92	$7.39M	2.9	86,206 shs	50,836 shs
XCUR Exicure	$1.21 -1.2%	$1.40	$1.05 ▼ $9.48	$7.99M	3.63	31,306 shs	2,571 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRIS Curis	0.00%	-17.01%	-44.30%	-90.61%	-97.54%
LGVN Longeveron	0.00%	+12.85%	-58.18%	-60.42%	-64.83%
SKYE Skye Bioscience	0.00%	-5.38%	-5.92%	-68.87%	-94.92%
XCUR Exicure	0.00%	-1.63%	-6.20%	-45.00%	-68.24%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRIS Curis	$0.83 +0.2%	$2.36	$0.80 ▼ $34.80	$1.73M	3.01	142,476 shs	158,284 shs
LGVN Longeveron	$2.63 -6.4%	$6.32	$2.30 ▼ $12.30	$8.96M	-0.25	177,635 shs	96,990 shs
SKYE Skye Bioscience	$1.61 -3.6%	$2.99	$1.50 ▼ $39.92	$7.39M	2.9	86,206 shs	50,836 shs
XCUR Exicure	$1.21 -1.2%	$1.40	$1.05 ▼ $9.48	$7.99M	3.63	31,306 shs	2,571 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRIS Curis	0.00%	-17.01%	-44.30%	-90.61%	-97.54%
LGVN Longeveron	0.00%	+12.85%	-58.18%	-60.42%	-64.83%
SKYE Skye Bioscience	0.00%	-5.38%	-5.92%	-68.87%	-94.92%
XCUR Exicure	0.00%	-1.63%	-6.20%	-45.00%	-68.24%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRIS Curis	2.00	Hold	$43.00	5,072.00% Upside
LGVN Longeveron	2.00	Hold	$80.00	2,941.83% Upside
SKYE Skye Bioscience	2.20	Hold	$64.00	3,875.16% Upside
XCUR Exicure	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest CRIS, LGVN, XCUR, and SKYE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	CRIS Curis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
9/8/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/8/2026	XCUR Exicure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/27/2026	SKYE Skye Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/25/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	CRIS Curis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/11/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	CRIS Curis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/28/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/24/2026	CRIS Curis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$17.00 ➝ $43.00
7/17/2026	CRIS Curis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRIS Curis	$9.44M	0.18	N/A	N/A	$8.45 per share	0.10
LGVN Longeveron	$1.20M	6.99	N/A	N/A	$2.47 per share	1.06
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$5.00 per share	N/A
XCUR Exicure	$500K	15.79	N/A	N/A	$0.62 per share	1.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRIS Curis	-$7.58M	-$14.22	N/A	N/A	N/A	-80.29%	-2,365.94%	-200.88%	11/5/2026 (Estimated)
LGVN Longeveron	-$22.70M	-$9.90	N/A	N/A	N/A	-1,977.59%	-223.19%	-150.20%	11/3/2026 (Estimated)
SKYE Skye Bioscience	-$55.92M	-$10.16	N/A	N/A	N/A	N/A	-329.08%	-201.79%	N/A
XCUR Exicure	-$4.95M	-$1.32	N/A	N/A	N/A	N/A	-237.91%	-61.98%	11/12/2026 (Estimated)

Latest CRIS, LGVN, XCUR, and SKYE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	CRIS Curis	-$6.95	-$4.02	+$2.93	-$4.02	$1.00 million	N/A
8/14/2026	Q2 2026	SKYE Skye Bioscience	-$0.29	-$0.27	+$0.02	-$2.4550	N/A	N/A
8/14/2026	Q2 2026	XCUR Exicure	-$18.60	-$0.18	+$18.42	-$0.18	$1.64 million	N/A
8/12/2026	Q2 2026	LGVN Longeveron	-$1.75	-$0.19	+$1.56	-$1.90	$0.33 million	$0.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRIS Curis	N/A	N/A	N/A	N/A	N/A
LGVN Longeveron	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A
XCUR Exicure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRIS Curis	N/A	0.49	0.49
LGVN Longeveron	N/A	2.63	2.63
SKYE Skye Bioscience	N/A	0.95	0.95
XCUR Exicure	N/A	0.56	0.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRIS Curis	29.97%
LGVN Longeveron	10.01%
SKYE Skye Bioscience	21.09%
XCUR Exicure	42.82%

Insider Ownership

Company	Insider Ownership
CRIS Curis	5.78%
LGVN Longeveron	7.42%
SKYE Skye Bioscience	6.20%
XCUR Exicure	52.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRIS Curis	24	2.09 million	1.97 million	No Data
LGVN Longeveron	38	3.19 million	2.95 million	Not Optionable
SKYE Skye Bioscience	12	4.43 million	4.15 million	Optionable
XCUR Exicure	50	6.55 million	3.09 million	Not Optionable

CRIS, LGVN, XCUR, and SKYE Headlines

Recent News About These Companies

Contrasting ProQR Therapeutics (NASDAQ:PRQR) & Exicure (NASDAQ:XCUR)

September 27 at 8:58 AM | americanbankingnews.com

Exicure stock falls 2.24 percent with Nasdaq deadline ahead

September 25 at 2:44 PM | ad-hoc-news.deA

Exicure Granted Extension By Nasdaq To Regain Compliance By Dec. '26

September 16, 2026 | rttnews.com

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement

September 16, 2026 | finance.yahoo.com

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement

September 16, 2026 | globenewswire.com

Exicure Announces Planned Issuance of Common Stock to Settle $1.0 Million Milestone Payment to GPCR Therapeutics

August 3, 2026 | quiverquant.comQ

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

August 3, 2026 | globenewswire.com

Exicure Inc (NASDAQ: XCUR) - Share Price and Research

July 15, 2026 | intelligentinvestor.com.auI

Exicure Reaches Preliminary Settlement in Derivative Lawsuits

July 9, 2026 | theglobeandmail.com

Exicure Announces Board and Committee Changes

June 30, 2026 | globenewswire.com

Exicure, Inc.: Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

June 11, 2026 | finanznachrichten.de

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement

June 10, 2026 | markets.businessinsider.com

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

June 10, 2026 | globenewswire.com

Exicure Regains Nasdaq Compliance After Late Quarterly Filing

June 1, 2026 | tipranks.com

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

June 1, 2026 | globenewswire.com

Exicure delays quarterly filing, trims quarterly loss

May 15, 2026 | tipranks.com

Exicure, Inc. and Adbiotech Co., Ltd. Announce Co-Development Agreement for Burixafor Combination Therapies

April 22, 2026 | quiverquant.comQ

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

April 22, 2026 | globenewswire.com

Exicure Inc.

April 13, 2026 | barrons.com

Exicure Strengthens Leadership With New COO and Director

April 10, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRIS, LGVN, XCUR, and SKYE Company Descriptions

Curis NASDAQ:CRIS

$0.83 +0.00 (+0.18%)

Closing price 04:00 PM Eastern

Extended Trading

$0.84 +0.01 (+0.67%)

As of 07:38 PM Eastern

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Longeveron NASDAQ:LGVN

$2.63 -0.18 (-6.41%)

Closing price 04:00 PM Eastern

Extended Trading

$2.71 +0.08 (+3.04%)

As of 07:03 PM Eastern

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Skye Bioscience NASDAQ:SKYE

$1.61 -0.06 (-3.59%)

Closing price 04:00 PM Eastern

Extended Trading

$1.63 +0.02 (+1.24%)

As of 07:30 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Exicure NASDAQ:XCUR

$1.20 -0.02 (-1.23%)

Closing price 03:57 PM Eastern

Extended Trading

$1.21 +0.01 (+0.58%)

As of 07:30 PM Eastern

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRIS, LGVN, XCUR, and SKYE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRIS, LGVN, XCUR, and SKYE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRIS, LGVN, XCUR, and SKYE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRIS, LGVN, XCUR, and SKYE Company Descriptions

Curis NASDAQ:CRIS

Longeveron NASDAQ:LGVN

Skye Bioscience NASDAQ:SKYE

Exicure NASDAQ:XCUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRIS, LGVN, XCUR, and SKYE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRIS, LGVN, XCUR, and SKYE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRIS, LGVN, XCUR, and SKYE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRIS, LGVN, XCUR, and SKYE Company Descriptions

Curis NASDAQ:CRIS

Longeveron NASDAQ:LGVN

Skye Bioscience NASDAQ:SKYE

Exicure NASDAQ:XCUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools